We’ve shared topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Full results will be presented at an upcoming medical meeting. #RNAitherapeutics #siRNA

Dr. Fontana, investigator on the HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy, shares thoughts on the topline results. Full data to be presented at an upcoming medical meeting.

#RNAinterference is a naturally occurring process of gene regulation that's already at work inside your body. #RNAi therapeutics, pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #science #biology #chemistry #biotech

HCPs: #hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice. bit.ly/3NuMgL9

Proteins are the "workers" in the biochemistry of life & are critical to almost everything your body does. They can also cause or contribute to disease. #RNAiTherapeutics, pioneered by Alnylam, prevent the production of specific unwanted proteins. #RNAi bit.ly/3oR8r2l

US Healthcare Professionals: Have a medical inquiry? Connect with Alnylam Medical via our RNAiScience website to use our MSL Locator tool or submit a Medical Information Request.

Well this looks like a fun group! A warm welcome to our 34 new co-ops from Northeastern U. University who started their Alnylam experience yesterday. They'll learn the business of #biopharma and support our mission by working in a wide range of functions. #RNAiRevolutionary

Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #ClinicalTrials.

We're celebrating being named a Fortune Best Workplace for Millennials for the 2nd year in a row! Thank you to our millennial colleagues whose passion and contributions power our mission to develop and deliver innovative #RNAiTherapeutics for patients in need.

Our #CorporateResponsibility (CR) efforts are driven by the passion of our employees to make a positive impact on the world beyond the medicines we make. Our 2023 report details our work, shares our progress and looks ahead to what we aim to accomplish in the years to come. #ESG

We'll be sharing 2nd Quarter 2024 financial results this Thursday, 8/1 at 8:30 AM ET, during a LIVE webcast. Register here: bit.ly/374c75E and access the replay at the same link later in the day. #RNAi #RNAitherapeutics #siRNA

We've reported Q2 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later today at: bit.ly/374c75E. $ALNY #RNAi #RNAiTherapeutics #siRNA

Happy #RNAday! RNA is A-mazing + critical to how your body functions. Did you know that a type of RNA called small interfering RNA (siRNA) can also be utilized to treat disease? #RNA #RNAinterference #RNAiTherapeutics #siRNA

We’re harnessing the potential of RNA interference (RNAi) and will be presenting new data at the European Society of Cardiology Congress 2024 8/30-9/2 in London. Learn more: bit.ly/3X4wxZL

As a pioneer in #RNA-based therapeutics, we relish opportunities to engage with peers and discuss what's new and next in nucleic acid medicines. If you do too, join us in La Jolla, CA Dec 9-11 for the nature #RNAbench2bedside conference. #RNAi #RNAinterference #siRNA

We're thrilled to be named to the #Humankind100 Top 100 list for the 3rd consecutive year by @Humankindinvest! Our passion for improving the health of humanity with the innovative medicines we make and robust community engagement is more than just a commitment – it's personal.

HCPs: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type.

Managing a #RareDisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it’s helpful to work with patient advocacy groups to answer questions and get more information. Hear from Kim Hollander of Oxalosis & Hyperoxaluria Foundation in an episode of Medical Stories. bit.ly/3ATSDVR

HCPs: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed.

Heard the news? We're a Fast Company Best Workplace for Innovators for the 4th year in a row! The list recognizes companies whose cultures empower employees at all levels to innovate, improve, create and transform ways of doing business that result in true impact. #AlnylamProud